Effects of cancer immunotherapy regimens on primary vs. secondary immune responses and the potential impact on long-term...
Published in Adv Exp Med Biol: Crossroads Between Innate and Adaptive Immunity II
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor ...
...Published in J Natl Cancer Inst
Proteasome Inhibition: Potential for Sensitization of Immune Effector Mechanisms in Cancer
Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network
Published in Immunology and Cell Biology
Differential effects of donor T cell cytokines on outcome with continuous bortezomib administration following allogeneic...
Published in Blood
Raising the specta of T-cell profiling
Published in Blood
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection
...Published in Blood
CTL-Promoting Effects of CD40 Stimulation Outweigh B Cell-Stimulatory Effects Resulting in B Cell Elimination and Diseas...
Published in Journal of Japan Society of Immunology & Allergology in Otolaryngology
The path(way) less traveled.
Published in Blood
In this issue of Blood, Mathewson et al characterized targeting a novel intracellular pathway with an agent known to induce potent antitumor effects but now also appears to potently suppress inflammatory responses by dendritic cells (DCs) and prevent graft-vs-host disease (GVHD). Identifying agents that can suppress GVHD yet not compromise graft-vs...
The authors reply.
Published in Transplantation Journal
